Calibr partners with Wellcome Trust to create consortium for neglected tropical diseases
August 3, 2021
LA JOLLA, CA—Calibr, the drug development division of Scripps Research, has partnered with Wellcome to launch the Integrated Drug Discovery Consortium for Neglected Tropical Diseases (IDDC-NTD). The three-year, $24 million grant will support Calibr in leveraging innovative approaches to address some of the most challenging neglected tropical diseases across the globe.
The initiative is part of Wellcome’s HIT NTD Flagship, which supports the development of exciting new products, technologies and other interventions to prevent or treat disease. The IDDC-NTD will harness Calibr’s existing drug discovery capabilities to advance medicines for a variety of pathogens pervasive in low-resource regions of the world.
“We’re very excited and thankful to partner with Wellcome to broaden our global health program and target important pathogens that collectively inflict a devasting toll on world morbidity and mortality,” said Case McNamara, PhD, director of Infectious Diseases at Calibr.
In parallel with other strategies, the program will utilize Calibr’s ReFRAME library, the world’s leading drug repurposing collection. Established in 2018 with support from the Bill & Melinda Gates Foundation, the ReFRAME collection was designed to tackle areas of urgent unmet medical need. It has since grown to comprise over 12,000 compounds, including drugs already known to be safe in humans for other indications.
Calibr additionally developed an open-source database containing preclinical and clinical data on these drugs, enabling the acceleration of new potential medicines into a patient setting without many of the obstacles typical to drug discovery. Since its inception, repurposed drugs have already been tested in clinical trials for tuberculosis and the parasite Cryptosporidium spp., a major cause of severe diarrheal disease.
As a partner of the HIT NTD Network, Calibr is integral to the Flagship program’s objective of supporting emerging technologies that can transform therapeutic development. These include the use of artificial intelligence, genomics and proteomics research, new reaction and drug delivery technologies, as well as advances in automation. The Flagship is also intended to serve as a hub for further innovation in this area, actively engaging a network of non-profit and for-profit partners to grow a portfolio of promising new treatments. In addition to researchers at Calibr, other collaborators on the program include Conor Caffrey, PhD, and Jair Siqueira-Neto, PhD, UC San Diego; Sumit Chanda, PhD, Sanford Burnham Prebys; Rick L. Tarleton, PhD, University of Georgia; Chris Huston, MD, University of Vermont; Jennifer Zambriski, DVM, PhD, Virginia Tech; Silmara Allegretti, PhD, The University of Campinas; Lizandra Guidi Magalhaes, PhD, University of Franca; and Jeremy Mottram, PhD, University of York.
Neglected tropical diseases (NTDs) encompass several diverse pathogens, including viruses, bacteria, protozoa and parasitic worms. Affecting more than 1 billion people, many of whom are living in extreme poverty, NTDs present significant barriers to global health. By building on the Wellcome’s prior investment of over $80 million in this area and combining it with the robust infrastructure and drug discovery team at Scripps Research, the IDDC-NTD is well-positioned to generate safe and effective new drugs, with the broader goal of intervening in the interlinked cycle of poverty and disease.
About Wellcome
Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, global heating and infectious diseases.
Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies
CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.
What’s next for IBD care: Insights from a surgeon-scientist
The data is clear: inflammatory bowel diseases like ulcerative colitis and Crohn’s are on the rise worldwide. In this episode, we sit down with Dr. Amy Lightner—VP of Clinical Development at Calibr-Skaggs and colorectal surgeon at Scripps Clinic—to explore what drives these diseases, an upcoming phase 2 clinical trial for a new regenerative medicine, and how she balances life between the operating room and the research lab.
Reprogramming the immune system: Precision immunotherapy for cancer and autoimmune disease
Your immune system is your body’s natural defense, capable of identifying what belongs and what doesn’t. But when it falters, it can let cancer grow unchecked or mistakenly attack your own healthy tissues, leading to autoimmune diseases. What if we could reprogram the immune system to tip the balance in our favor, gaining an advantage over both cancers and autoimmune disorders? In this Front Row lecture, Calibr-Skaggs’ vice president of biologics, Travis Young, shared how Scripps Research is using genetic engineering to reprogram patients’ own immune cells to create personalized “switchable” CAR-T cell therapies. This approach represents a new class of precision immunotherapy designed to induce deep and durable remissions in patients with a wide range of cancers, from lymphoma to breast cancer, as well as in chronic autoimmune conditions such as lupus, rheumatoid arthritis and systemic sclerosis. Young explained how this breakthrough strategy works and what it could mean for the future of medicine.
Viome and Scripps Research partner to develop first at-home RNA screening test to prevent colon cancer before it strikes
First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous.Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions.